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Summary
Phosphorylation is critical to regulation of the eukary-
otic cell cycle. Entry to mitosis is triggered by the
cyclin-dependent kinase CDK1 (Cdc2), which is inac-
tivated during the preceding S and G2 phases by
phosphorylation of T14 and Y15. Two homologous ki-
nases, Wee1, which phosphorylates Y15, and Myt1,
which phosphorylates both T14 and Y15, mediate this
inactivation. We have determined the crystal struc-
ture of the catalytic domain of human somatic Wee1
(Wee1A) complexed with an active-site inhibitor at
1.8 Å resolution. Although Wee1A is functionally a ty-
rosine kinase, in sequence and structure it most
closely resembles serine/threonine kinases such as
Chk1 and cAMP kinases. The crystal structure shows
that although the catalytic site closely resembles that
of other protein kinases, the activation segment con-
tains Wee1-specific features that maintain it in an
active conformation and, together with a key substitu-
tion in its glycine-rich loop, help determine its sub-
strate specificity.
Introduction
Typical eukaryotic cells cycle through four phases dur-
ing cell division: G1, S (DNA synthesis), G2, and M (mi-
tosis). This process must accurately replicate the par-
ent cell’s genetic material in the S phase and distribute
identical chromosomal copies evenly between two
daughter cells at M phase. Progress through the cell
cycle is coordinated by the actions of CDKs (cyclin-
dependent kinases) that are activated by association
with specific cyclin proteins (for reviews, see Pines,
1993; Morgan, 1997). CDK activity is further regulated
through posttranslational modification of the CDKs,
transcriptional control, the association of cofactors, in-
tracellular localization, and the balance between syn-
thesis and degradation of cyclins and other regulators
(Morgan, 1995; Pavletich, 1999; Malumbres and Bar-
bacid, 2001). Defects in this strict regulation of the cell
cycle can result in the development of tumors and other
diseases that involve diverse cellular processes includ-
ing apoptosis, differentiation, angiogenesis, and inflam-
mation.
In higher eukaryotes, entry to mitosis is triggered by
the key CDK known as Cdc2 (CDK1). The activity of
CDK1 is regulated both by association with B type*Correspondence: ted.baker@auckland.ac.nzcyclins and by activating and inhibitory phosphoryla-
tion (Dunphy, 1994; Morgan, 1997). The association of
CDK1 with cyclin B during S phase facilitates the phos-
phorylation of CDK1 at T14, Y15, and T161 (Atherton-
Fessler et al., 1993; Draetta et al., 1988; Meijer et al.,
1991; Parker et al., 1991; Solomon et al., 1992). T161
phosphorylation allows stable association with cyclin B
that is essential for CDK1 activation and the initiation
of mitosis. On the other hand, phosphorylation of T14
and Y15 is required to maintain CDK1 in an inactive
state during the preceding S and G2 phases.
The inhibitory inactivation of CDK1 is mediated by
enzymes of the Wee1 kinase family, which thus play a
critical role in the cell cycle by controlling the entry
into mitosis. In humans and other vertebrates, Y15 is
phosphorylated by Wee1 kinase (Honda et al., 1992;
McGowan and Russell, 1993; McGowan and Russell,
1995; Parker and Piwnica-Worms, 1992; Watanabe et
al., 1995), and another Wee1 family member, the mem-
brane bound, dual-specificity Myt1 kinase, phosphory-
lates both T14 and Y15 (Liu et al., 1997; Mueller et al.,
1995). Late in G2, Cdc25 phosphatase dephosphory-
lates T14 and Y15, activating CDK1 and thus promoting
mitosis (Dunphy and Kumagai, 1991; Gautier et al.,
1991; Sebastian et al., 1993).
Wee1 kinase is itself regulated by phosphorylation
and degradation (Watanabe et al., 1995). Phosphoryla-
tion of residues in its N-terminal domain, described be-
low, generates a phospho-degron (signal for degrada-
tion) that allows recognition by an F box protein and
targets Wee1A for ubiquitination and degradation (Wa-
tanabe et al., 2004). Removal of Wee1 thus promotes
entry into mitosis (Ayad et al., 2003; Watanabe et al.,
2004). Phosphorylation of the C-terminal tail allows 14-
3-3 peptides to bind to Wee1A, an event that influences
the intracellular distribution of Wee1 and its level of ac-
tivity (Wang et al., 2000; Lee et al., 2001). Recent evi-
dence shows that Wee1 levels are also controlled by
components of the circadian clock, making it the key
link between the circadian clock and the cell cycle, and
hence cellular proliferation (Matsuo et al., 2003).
The role of Wee1 in controlling entry to mitosis also
gives it considerable potential as a drug target. Cellular
DNA damage can initiate the G2 checkpoint, a pause
at G2 that prevents the cell from entering mitosis, pre-
sumably giving time for other cellular mechanisms to
make repairs. Experiments in fission yeast indicate that
the G2 checkpoint functions by maintaining Y15 phos-
phorylation on CDK1 until DNA damage is repaired
(O’Connell et al., 1997; Rhind et al., 1997). As a regula-
tor of CDK1 Y15 phosphorylation, Wee1 is thus integral
to this G2 checkpoint function, and Wee1 inhibitors
have potential use as G2-abrogating compounds. As
one example, studies using seven cancer cell lines
lacking a functional p53 demonstrated that inhibition of
Wee1 with a nanomolar inhibitor, PD0166285, effec-
tively abrogated the G2 checkpoint (Wang et al., 2001).
This allowed the p53−/− cells to proceed to premature
mitosis and cell death, suggesting that effective Wee1
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linhibition might be used in this way to enhance conven-
tional cancer therapy. N
pIn humans, two Wee1 kinases with different temporal
and spatial expression, Wee1A and Wee1B, have been w
icharacterized (Nakanishi et al., 2000). The somatic
Wee1 kinase, Wee1A, is a 646 amino acid protein (Wa- α
htanabe et al., 1995) comprising three domains: a long
N-terminal regulatory domain, a central kinase domain, t
Nand a short C-terminal regulatory domain (Figure 1).
The N-terminal domain contains two phosphorylation t
ksites, at Ser53 and Ser 123, which provide the signal
that targets Wee1 for destruction. It also contains three
apotential PEST regions (Watanabe et al., 1995) and a
putative nuclear localization signal (Arg-Arg-Arg-Lys- P
AArg). Phosphorylation of the penultimate residue in the
short C-terminal domain, Ser645, generates the 14- s
m3-3 binding site. Although it has a strict specificity for
phosphorylation of Y15 in CDK1, the central kinase do- A
smain of Wee1A is not a typical tyrosine kinase. Se-
quence searches of the human genome do not place i
cWee1A in any of the identified tyrosine kinase subfami-
lies (Robinson et al., 2000), and comparisons with the a
bfull complement of protein kinases place Wee1A and
Myt1 in a separate family (Manning et al., 2002). v
lHere we present the 1.8 Å crystal structure of the
kinase domain of Wee1A, complexed with a known in- i
(hibitor of full-length Wee1A kinase, PD0407824 (Booth
et al., 2003). The structure, which is to our knowledge m
tthe first for any Wee1 family member, reveals a close
structural relationship with prototypical serine/threo- d
Pnine kinases, coupled with Wee1-specific sequence
changes. These differences maintain Wee1A in an active
wconformation and provide a basis for understanding the
substrate specificity of Wee1A. The structure also pro- m
tvides a starting point for structure-based drug design
of Wee1 inhibitors for cancer therapy. f
2
SResults and Discussion
(
2Structure Determination
Sequence and structural alignments of other kinase do- c
bmains led to the design of a construct comprising resi-
dues 291–575 of human Wee1A kinase, which was then f
texpressed in Sf9 insect cells. The crystal structure was
solved by single isomorphous replacement with anom- p
Walous scattering (SIRAS) and refined at 1.8 Å resolution
to an R factor of 0.218 (Rfree = 0.237). Statistics for the T
sstructure determination and refinement are given in Ta-b
d
p
w
a
dFigure 1. Domain Structure for Human Somatic Wee1 Kinase
(Wee1A) d
The N-terminal regulatory domain is shown as an open box with e
the known serine phosphorylation sites (S53 and S123) and nuclear w
localization signal (NLS) indicated. The kinase domain is indicated r
by a gray box, with the first and last residues of the construct ex-
Cpressed in this work indicated. The C-terminal serine residue impli-
cated in 14-3-3β binding is also indicated (S642).
Ole 1. The final model comprises 258 amino acid resi-
ues; the inhibitor PD0407824 (9-hydroxy-4-phenyl-6H-
yrrolo[3,4-c]carbazole-1,3-dione); 2 Mg2+ ions, which
ere identified as such by their coordination geometry;
nd 144 water molecules. All 279 residues of the kinase
omain construct have been modeled except for resi-
ues 436–455 and 570–575, which had no interpretable
lectron density. The polypeptide has good geometry,
ith 91.5% of nonglycine residues in the most favored
egions of the Ramachandran plot, as defined in PRO-
HECK (Laskowski et al., 1993), and only one outlier.
verall Structure
he Wee1A catalytic domain displays a standard two-
obed kinase fold (Figure 2A). The mainly β sheet
-terminal lobe is folded around a five-stranded anti-
arallel β sheet and has the typical glycine-rich loop,
ith consensus sequence GxGxxG (residues 306–311
n Wee1A), that is found in other kinases. The mainly
-helical C-terminal lobe contains a characteristic four-
elix bundle. The two lobes are joined by a linker pep-
ide (residues 377–381) that connects strand β5 in the
lobe to helix αD in the C lobe; this has been shown
o allow relative movement of the two lobes in other
inases, for example cAMPK (Narayana et al., 1997).
The active-site cleft is located between the two lobes
nd provides the binding site for the Wee1A inhibitor
D0407824 (Figure 2B), an antagonist of the natural
TP substrate. The active-site region contains a short
ection of extended polypeptide (the catalytic seg-
ent) that includes the essential catalytic aspartate
sp426, and a large loop, referred to as the activation
egment, that provides a substrate binding platform
n protein kinases and can undergo conformational
hanges that control the activation state (Johnson et
l., 1996). A sequence alignment of Wee1 family mem-
ers from various species suggests structural conser-
ation across the whole kinase domain (Figure 3). The
oop 436–455, not located in the structure, has been
dentified from its sequence as a potential PEST region
Watanabe et al., 1995). PEST regions are found in
any short-lived eukaryotic proteins and play a role in
heir degradation (Rogers et al., 1986). The solvated,
isordered nature of this loop is consistent with its
EST annotation.
A search of the current protein structure database
ith SSM (http://www.ebi.ac.uk/msd-srv/ssm/) reveals
any protein kinases that can be superimposed onto
he Wee1A kinase domain with root-mean-square dif-
erences in Cα positions of less than 2.0 Å over 220–
40 residues. The closest structural matches are mostly
er/Thr kinases, including the active forms of CDK2
Jeffrey et al., 1995), Aurora kinase (Nowakowski et al.,
002), and Chk1 kinase (Chen et al., 2000); these cell
ycle-associated kinases are all close metabolic neigh-
ors to Wee1A. It is notable that the top hits are all
unctionally Ser/Thr kinases and that not until the four-
eenth-highest hit is a Tyr kinase encountered. Although
rotein kinases vary widely in amino acid sequence, the
ee1A sequence is also more closely related to Ser/
hr kinases than to Tyr kinases. This is illustrated by a
imple BLAST comparison (Altschul et al., 1997) of the
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543Table 1. Crystallographic Statistics
Crystal Native1 Native2 Hg
Data collection statisticsa
Resolution (Å) 1.81 (1.87–1.81) 2.25 (2.33–2.25) 2.60 (2.69–2.60)
Reflections measured 734,175 189,188 750,884
Unique reflections 34,834 19,169 12,493
Completeness (%) 95 (92) 95 (77) 100 (99)
Average I/σ 23 (2.6) 25 (4.9) 45 (13)
Rmergeb 0.082 (0.362) 0.079 (0.401) 0.081 (0.275)
SIRAS statistics (phasing to 3.0 Å resolution)
SOLVE FOM (3 × Hg) 0.32
SOLVE z-score 12.07
Resolve FOM 0.63
Refinement statistics
Resolution (Å) 47–1.81
Reflections (F > 0.0) 34,800
Total non-H atoms 2213
Rcrystc 0.218
Rfreed 0.237
Residues in most favored regions of the Ramachandran 90.5
plot (%)
Rmsd ideal bond length (Å) 0.022
Rmsd ideal bond angles (o) 2.09
a Data for the highest resolution shell is given in parentheses
bRmerge = S|Ii − <I>|/SIi
cRcryst = S||Fobs|-|Fcalc||/S|Fobs|, calculated for the 95% data used in refinement
dRfree = same as for Rcryst but using only the 5% of the data excluded from refinementWee1A catalytic domain sequence with consensus se-
quences for Ser/Thr kinases and Tyr kinases; expecta-
tion values of 6e-40 and 3e-22, respectively, show that
Wee1A shares features of both but is more Ser/Thr ki-
nase-like. A dendrogram of 491 eukaryotic protein ki-
nase domain sequences (Manning et al., 2002) likewise
recognizes Wee1 as a separate family, closest to sev-
eral Ser/Thr kinase families. Taken together, the sequence
and structural comparisons, and the Myt1-Wee1 famil-
ial relationship, suggest that the Wee1-family proteins
may have evolved from a Ser/Thr kinase, a few key mu-
tations converting Wee1 to a Tyr kinase that acts on
CDK1.
Active Site
The well-defined active-site cleft is bounded by the
five-stranded β sheet and glycine-rich loop from the N
lobe, which curve over it from above; the β5-αD con-
necting loop (the hinge region), which defines the end
of the cleft; and two parts of the C lobe, helix αD and
the catalytic segment, which make up the other wall
of the cleft. The floor is formed by the N lobe helix αC
and the region between β8 and β9 leading into the acti-
vation segment. Many invariant or conservatively sub-
stituted residues are found in the active site, particu-
larly in the catalytic segment.
The catalytic segment, residues 422–433, extends
from strand β6 to the beginning of strand β7 and pres-
ents the essential catalytic aspartate, Asp426, into the
active-site cleft. Its sequence, which is highly con-
served (Figure 3), contains the active-site motif HxD
and closely matches the protein kinase consensus se-
quence IVHxDLKPxNIx. The residue preceding Asp426is often an arginine in kinases that are activated by
phosphorylation of residues in the activation segment,
referred to as RD kinases (Johnson et al., 1996). In
Wee1A, however, the preceding residue is nonpolar
Met425, which forms part of a hydrophobic cluster with
Val487 and Leu495 that helps to anchor the activation
segment by interaction with Val475.
Superposition of the Wee1A structure onto the inhibi-
tor or ATP bound structures of cAMPK and Chk1 ki-
nases (Zheng et al., 1993; Chen et al., 2000) shows a
close overlay of the catalytically important residues
(Figure 4A), including one of the two Mg2+ ions found
in the Wee1A structure. This Mg2+ is bound to Asn431
from the catalytic segment and Asp463 from the start
of the activation segment, together with three water
molecules, and has a coordination environment virtu-
ally identical to that of the catalytically important Mg2+
ion in the cAMPK/ATP structure. The sixth coordination
site is vacant in both structures.
One intriguing variation exists in the catalytic seg-
ments. In cAMPK and Chk1, the carboxyl group of the
catalytic aspartate (Asp166 in cAMPK, Asp130 in Chk1)
is hydrogen bonded to a threonine residue (Thr170 in
Chk1) that contributes to the specificity of Ser/Thr ki-
nases versus Tyr kinases (Taylor et al., 1995). This helps
position the aspartate side chain for its role in catalysis.
In Wee1A, however, this threonine is substituted by
Asp479 (a Wee1-specific substitution), precluding a
similar interaction with the catalytic Asp426. Instead,
Asp426 is held in an appropriate geometry by hydrogen
bonds with Asp479 NH and a network of water mole-
cules, and by coordination to the Mg2+ ion bound to
Asn431. A water molecule directly in front of Asp426
Structure
544Figure 2. X-Ray Structure of the Wee1A/PD0407824 Complex
(A) Ribbon diagram showing the canonical two-lobe protein kinase fold with inhibitor PD0407824 (ball-and-stick model) binding in the active-
site cleft between the N and C lobes, hydrogen bonding to the hinge region. Two Mg2+ ions are shown as yellow spheres. β strands are
colored blue, α helices green, the catalytic (CS) and activation (AS) segments red. Figure prepared with Ribbons (Carson, 1997).
(B) Electron density for the PD0407824 inhibitor bound to Wee1A, contoured at a level of 3 σ from an Fo − Fc omit map. Hydrogen bonds
linking the inhibitor to the hinge region (residues 376–379) and to the two well-ordered water molecules, W614 and W724, are shown with
broken lines. Drawn with Ribbons (Carson, 1997).
(C) Stereo Cα plot for the Wee1A catalytic domain structure. Every tenth residue is indicated with a small green sphere.mimics a substrate tyrosine hydroxyl. A similarly placed C
water molecule is found in cAMPK, where it is sug- 2
gested to function as a nucleophile, initiating hydrolysis i
(Madhusudan et al., 2002). r
dATP and Inhibitor Binding
wCrystals of Wee1A were only obtained when the protein
iwas complexed with high-affinity inhibitors, suggesting
Nthat inhibitor binding may have induced some confor-
mational change and/or stabilization of the structure. aonsistent with this, the inhibitor PD0407824 (Figure
B) is bound deeply in the active-site cleft, largely bur-
ed within the protein, in a mostly hydrophobic envi-
onment.
Inhibitor binding is marked by highly favorable hy-
rogen bonding with surrounding protein groups, in
hich the maleimido ring plays a key role. It is located
nternally, with its two oxygen atoms and intervening
H hydrogen bonded to main chain and side chain
toms of residues 376–379 of the β5-αD loop, which
Structure of Human Wee1 Kinase
545Figure 3. Multiple Sequence Alignment of Wee1 Kinase Family Members
The sequence numbering is that of human Wee1A kinase, with the Wee1A secondary structure shown above the alignment. Invariant residues
(white on red background) and conservatively substituted residues (red) in the Wee1 family are indicated. Unique Wee1 residues are marked
with an asterisk and are defined as those residues conserved in Wee1 but not found in protein kinase, serine/threonine kinase, or tyrosine
kinase consensus sequences from the BLAST database (Altschul et al., 1997). The catalytic and activation segments are indicated with a red
bar. Sequences shown are for Wee1A kinase of human (hu), mouse (mm), Carassius auratus (ca), Drosophila (dm), and Arabidopsis (at);
Wee1B kinase of Xenopus (Weeb_xl); Mik1 kinase of S. pombe (Mik1_sp); and Myt1 kinase of human (Myt1_hu). Figure prepared using ESPript
(Gouet et al., 1999).forms the hinge region at the back of the cleft, and to
the first of two very well-defined water molecules,
W614 and W724 (Figure 2B). Both waters are tetrahe-
drally coordinated, completing a network of interac-
tions between the inhibitor and the protein structure.
W614 sits over the inhibitor phenyl ring, which occupies
a pocket bounded by hydrophobic side chain atoms
of Val313, Lys328, and Ile374. Further stabilization of
inhibitor binding is provided by the packing of side
chains against the planar carbazole ring system: the
conserved Wee1 residue Phe433 stacks against one
face of the ring system; Ile305 and Val313, which imme-
diately precede and follow the glycine-rich loop, and
Ala326 from strand β3 together present a hydrophobic
surface to the other face. The glycine-rich loop itself,
residues 306–311, makes no close contacts with
PD0407824 and has higher B factors than the rest of
the active-site region. The most exposed part of the
inhibitor is the edge of the carbazole moiety, including
its pyrrole nitrogen.
Comparisons with other protein kinase inhibitor com-
plexes (reviewed in Noble et al., 2004) show that
PD0407824 has particular features that enhance bind-
ing in Wee1A. Thus, although the core structure of the
protein kinase inhibitor staurosporine is similar to that
of PD0407824, its IC50 for inhibition of Wee1A is more
than 100× higher (26 M compared with 97 nM for
PD0407824). By consideration of the mode of stauro-
sporine binding found for Chk1 (Zhao et al., 2002), we
attribute the stronger Wee1A inhibition by PD0407824
to (1) the additional hydrogen bonds made by the sec-
ond maleimido oxygen, and (2) improved hydrophobic
interactions and reduced steric repulsion resulting from
its rotatable phenyl substituent and lack of the tetrahy-
dropyran ring of staurosporine (which would clash
with Phe433).Attempts to cocrystallize Wee1A with staurosporine,
or with ATP or ATP analogs, have been unsuccessful.
This may be because of their lower affinity, but it may
also reflect a change in the closure of the glycine-rich
loop over the PD0407824 inhibitor, which could affect
crystal packing. Differences of this type, accompanying
ligand binding, have been seen for cAMPK (Narayana
et al., 1997).
Modeling ATP binding (Figure 4B) shows that the ad-
enine moiety binds in the hydrophobic pocket formed
by Ile305, Val313, Ala326, and Phe433, occupied by the
carbazole system in the inhibitor bound structure. The
modeling places the ATP adenine more shallowly in the
active site than PD0407824, however, with fewer con-
tacts to the protein backbone, hydrogen bonding only
to Glu377 O. This is entirely consistent with their rela-
tive binding affinities, with ATP binding at least three
orders of magnitude more weakly than the PD0407824
inhibitor (A.J. Kraker, personal communication). Two ly-
sine residues, Lys328 and Lys428 (equivalent to Lys72
and Lys168 in cAMPK), are positioned such that Lys328
can hydrogen bond to the α- and β-phosphates, and
Lys428 to the γ-phosphate and the catalytic Asp426,
like their analogs in cAMPK (Zheng et al., 1993). Lys428
is not found in other Tyr kinases but is conserved
among Ser/Thr kinases.
Conformation of the Activation Segment
The activation segment is a key functional region of
protein kinases that extends from the back of the active
site, where a conserved Asp residue (Asp463 in Wee1A)
binds the essential Mg2+ ion, and forms an irregular ex-
tended loop that finishes with helix αEF in the C-ter-
minal domain (Figure 2A). In many kinases this loop can
undergo conformational changes, dependent on the
Structure
546Figure 4. Stereo Views of the Catalytic Sites
of Wee1A and cAMP Kinase
(A) Overlay of the Wee1A/PD0407824 and
cAMP kinase/ATP structures. The Wee1A Cα
ribbon is shaded dark gray and the cAMP
ribbon is outlined in black (side chains are
shaded similarly). Hydrogen bonds are indi-
cated with broken lines. The experimentally
located magnesium ions found in the two
structures are shown as larger spheres. After
superposition, the catalytic sites have a root-
mean-square difference in Cα atomic posi-
tions of 0.76 Å for the residues shown.
(B) Wee1A/ATP model. The ATP molecule,
the tip of the glycine-rich loop, the side chain
of Lys328, and a second magnesium (Mg2)
were modeled on the basis of the cAMP ki-
nase/ATP structure. The ATP base hydrogen
bonds to Glu377 O at the back of the active
site while the phosphates coordinate the two
magnesium cations, Lys328, and Lys428.
Both figures drawn with MolScript (Kraulis,
1991).phosphorylation state of certain residues (Johnson et g
Aal., 1996).
In Wee1A the activation segment is 25 residues in f
Hlength, residues 462–486. It is well ordered throughout
its whole length, with a conformation that corresponds e
Nvery closely to that of the activation segments in Chk1
(Chen et al., 2000), Aurora kinase (Nowakowski et al., t
a2002), and phosphorylase kinase (Owen et al., 1995),
none of which appear to require phosphorylation for ac- b
btivation. Structural superpositions show that 21 Cα
atoms of the Wee1A activation loop can be superim- t
posed on the corresponding atoms of Chk1, Aurora ki-
nase, and phosphorylase kinase with rms differences s
aof 1.56, 1.55, and 1.62 Å, respectively. The activation
loop does not occlude any part of the active site such m
ithat it could prevent either ATP or substrate peptide
binding. We conclude, therefore, that it is also in an 1
uactive conformation in our Wee1A structure.
Like that in Chk1, the Wee1A activation segment is h
pstabilized in its active state by secondary structure and
side chain interactions. In the N-terminal half of the ac- A
ftivation segment, a short β strand, β9 (468–470), pairs
with β6 in the C-terminal domain, and the tip of the loop A
rhas consecutive β turns, 469–472 and 472–475, that are
buttressed against the C lobe by hydrophobic inter- B
actions through Ile470 and Val475. Side chain hydro-en bonds between Thr468 and Ser472, and between
rg469 and the C terminus of helix αC in the N lobe,
urther stabilize this portion of the activation segment.
ydrophobic interactions involving side chains at each
nd of the activation segment (Leu464 and Val467 at its
-terminal end and Leu483 at its C-terminal end) fur-
her anchor it to the C-terminal lobe, as does an invari-
nt kinase ion pair between Glu486 and Arg557. A num-
er of well-ordered water molecules form bridges
etween the activation segment and residues in both
he N-terminal and C-terminal lobes.
Many of the side chains that stabilize the activation-
egment conformation are contributed by residues that
re invariant or highly conserved in all Wee1 family
embers and differ from the sequence patterns seen
n other protein kinases (Figure 3). Of the 25 residues,
7 are strongly conserved in the Wee1 family and 7 are
nique to it. This suggests that the conformation seen
ere is common to all Wee1 family members and has
articular functional importance. Of particular note is
sp479, one of the Wee1-specific residues, which
orms a doubly hydrogen-bonded salt bridge with
rg481, holding it in a position in which it can play a key
ole in substrate recognition and binding (see Substrate
inding and Specificity).
Our structure suggests that regulation of Wee1A is
Structure of Human Wee1 Kinase
547achieved not by conformational changes in the activa-
tion segment but through regions outside the catalytic
domain. This is consistent with previous experiments
suggesting that regulation of Wee1 kinases is achieved
through its N- and C-terminal regulatory domains, both
by phosphorylation (Watanabe et al., 1995) and by 14-
3-3 binding (Lee et al., 2001; Wang et al., 2000). Recent
results with both Xenopus and human Wee1 proteins
demonstrate that phosphorylation of serine residues in
their N-terminal domains induces recognition by F box-
containing proteins of the SCF E3 ubiquitin ligase com-
plex and targets Wee1 for destruction (Ayad et al.,
2003; Watanabe et al., 2004). This temporary removal
of Wee1 leads to timely entry into mitosis.
Substrate Binding and Specificity
The structure of the Wee1A kinase catalytic domain
provides a basis for understanding the specificity of
this enzyme, which is so critical to the G2 checkpoint
and proper entry into mitosis in the cell cycle. The natu-
ral substrate is CDK1, which is specifically phosphory-
lated on Y15, located in its glycine-rich loop (sequence
GEGTYG, residues 11–16). Attempts to cocrystallize
Wee1A or soak Wee1A crystals with 10- or 20-residue
peptides containing this target sequence were unsuc-
cessful, presumably because binding depends also on
parts of the CDK1 structure outside this region. We
therefore docked an octapeptide with an appropriate
sequence onto our Wee1A structure, as described in
Experimental Procedures. In doing so, we assumed
that the substrate peptide has sufficient flexibility to
conform to the contours of the Wee1A surface. The
presence of three glycines and the known flexibility of
this glycine-rich region in other protein kinases, includ-
ing the very closely related CDK2, support this as-
sumption.
The need to position Y15 for phosphorylation, with
its hydroxyl replacing a water molecule from the Wee1A
crystal structure, imposes some constraints on where
the peptide must bind. In this proposed binding mode
(Figure 5A), the peptide occupies a shallow groove on
the Wee1A surface, passing between the side chains
of two arginine residues, Arg481 and Arg518, under
Glu309 from the Wee1A glycine-rich loop, and dockingFigure 5. Model for Peptide Binding to
Wee1A
(A) The peptide Gly-Glu-Gly-Thr-Tyr-Gly-Val-
Val (residues 11–18 of human CDK1) is shown
as a stick model, color coded by atom type.
Putative hydrogen bonds are shown as broken
lines. The peptide passes between Arg518
and Arg481, partly hidden below it, and a hy-
drogen bond to T14 helps position Y15 for
phosphorylation by Wee1A. Glu309 would
limit the approach of substrate for phos-
phorylation at T14. Figure drawn with SYBYL
(Blanco, 1991), with solvent-accessible sur-
faces calculated with a probe radius of 1.4 Å
and colored by electrostatic potential (nega-
tive potential blue, positive potential red, and neutral regions green, as indicated by the color-bar legend).
(B) Specific difference between Wee1 kinases and other tyrosine kinases in the peptide binding region, shown by comparison of Wee1A
(green) with the insulin receptor tyrosine kinase IRK3 (mauve). In typical tyrosine kinases, the arginine residue equivalent to Arg481 hydrogen
bonds to a nearby loop, causing a surface bulge. In Wee1A, however, Arg481 is sequestered by a Wee1-specific salt bridge with Asp479 that
instead creates a shallow groove, assisted by an invariant leucine. Drawn with Ribbons (Carson, 1997).V17 of the peptide into a hydrophobic pocket. The Y15side chain is positioned in the active site for phosphoryl
transfer, whereas the preceding T14 side chain is ori-
ented outwards and can hydrogen bond to Arg518.
From the Wee1A structure, two Wee1-specific features
seem likely to play important roles in substrate specific-
ity. First, Arg481 in the activation loop is the site of a
key structural deviation from other tyrosine kinases, in
which an equivalent arginine forms a surface bulge as-
sociated with a conserved PxR (or PxK) sequence motif
in the activation segment (Figure 5B). In Wee1A, in con-
trast, Arg481 is sequestered by a salt-bridge interaction
with the Wee1-specific Asp479. This removes the bulge
and results in the surface groove in which the substrate
peptide is docked in Figure 5A. Second, for phosphory-
lation of T14 the peptide would have to approach more
closely the glycine-rich loop of Wee1A. The presence
of the Glu309, another Wee1-specific feature, at the tip
of this loop may inhibit this closer approach in the same
way that phosphorylation of Thr14 or Tyr15 in CDK1
is believed to inhibit substrate binding through steric
hindrance (Endicott et al., 1999).
Conclusion
Wee1 kinase plays a key role in cell cycle regulation by
inactivating the cell cycle kinase Cdc2 (CDK1) through
phosphorylation of Y15 on CDK1. This inactivation is
important in preventing entry into mitosis until DNA
damage is repaired, giving Wee1 an important function
in the G2 checkpoint. Our crystal structure of the hu-
man Wee1A catalytic domain shows that Wee1 is an
atypical tyrosine kinase in that it groups most closely
with Ser/Thr rather than Tyr kinases. Its specificity
for CDK1 Y15 phosphorylation appears to arise from
Wee1-specific features in its activation loop, coupled
with the presence of Glu309 in the glycine-rich loop of
Wee1A, which may disfavor phosphorylation of the pre-
ceding CDK1 T14 residue by steric hindrance.
The importance of substitutions in the glycine-rich
loop in controlling activity is a recurring theme in pro-
tein kinases and arises because of the need for this
flexible loop to fold over ATP for stable binding. In
CDK1 and CDK2, phosphorylation of the glycine-rich
loop residues T14 and Y15 (equivalent to Glu309 and
Phe310 in Wee1A) causes inactivation by disfavoring
protein-substrate binding and/or productive ATP bind-
Structure
548aing (Endicott et al., 1999; Bartova et al., 2004). By anal-
cogy, we propose that the Wee1-specific presence of
Glu309 in the glycine-rich loop influences substrate
specificity in a similar way. S
The Wee1A crystal structure, in complex with a nano- T
molar inhibitor, provides a starting point for structure- p
dbased drug design of inhibitors that might be targeted
lat Wee1A itself or at other Wee1 family members. Inhi-
ebition of human Wee1A has been shown to induce pre-
1mature entry into mitosis, before DNA damage has
T
been repaired at the G2 checkpoint (Wang et al., 2001), i
demonstrating the potential use of such inhibitors as u
enhancers of conventional cancer therapy. Our struc- a
cture defines features of Wee1A sequence and surface
utopology that could be targeted by inhibitor molecules
cin this and other Wee1 family members, and the binding
cmode of the PD0407824 molecule provides a guide to
e
positions that might be appropriate for medicinal p
chemistry or combinatorial chemistry substitutions i
(provisional US patent application filed May 29, 2003, o
sUS Serial No. 60/473887).
p
(
Experimental Procedures F
TConstruct Design, Expression, and Purification
a
The construct used for the structure analysis, comprising residues
291–575 of human somatic Wee1A kinase (Wee1A291–575), was cho-
sen on the basis of molecular-modeling experiments. Superpo- M
sition of seven tyrosine kinase structures downloaded from the
AHOMSTRAD website (Mizuguchi et al., 1998) led us to choose ap-
Spropriate start and end points that would not compromise the in-
(tegrity of the catalytic domain.
sHuman U937 cells (T cell lymphoma) were used as a source of
tmRNA for human Wee1A291–575 cDNA production. Amplicons using
Mthe above primers were generated from U937 cDNA via the poly-
imerase chain reaction using Platinum Pfx DNA Polymerase (Invitro-
Pgen). The amplicons were purified using a High Pure PCR kit
w(Roche), restricted with NcoI and EcoRI, and ligated into the NcoI/
mEcoRI sites of the pFastBacHTb vector. The resultant recombinant
tplasmids produced an in-frame fusion of the human Wee1A se-
dquence with the vector His-tag and rTEV cleavage sequences
3downstream of the polyhedrin promoter. Human Wee1A291–575 was
cpurified from Sf9 insect cells by 6×His affinity chromatography
Wusing Talon resin (CLONTECH), rTEV cleavage, dialysis, affinity
schromatography, and, finally, size-exclusion chromatography on a
pSuperdex 200 HR 10/30 column (Pharmacia).
b
t
Crystallization and Data Collection (
A 50 µl aliquot of Wee1A291–575 protein (concentration w7 mg/ml)
was mixed with 2.5 µl of PD0407824 (9-hydroxy-4-phenyl-6H-pyr-
C
rolo[3,4-c]carbazole-1,3-dione) at a 4 mM concentration in dimethyl
c
sulfoxide. Crystals were grown in hanging drops by mixing equal
tvolumes of the protein complex and the reservoir solution, com-
mprising 100 mM HEPES (pH 7.5), 4.3 M NaCl. Crystals formed in
c2–3 days, growing to approximately 0.5 mm in their longest dimen-
Tsion within 3 weeks. The crystals were dipped briefly in a solution
Wcontaining 85% (v/v) reservoir and 15% (v/v) glycerol, and flash-
bfrozen in liquid nitrogen for data collection. Data to 1.8 Å resolution
swere collected at −170°C at the undulator beam line 17-ID of APS
Cusing a 165 mm MarResearch CCD detector with Pt/Pd-coated
ULE mirrors. The crystals belong to space group P41212 with unit
cell dimensions a = b = 69.78, c = 157.02 Å. An additional 2.25 Å
resolution native data set was collected at −160°C on a Rigaku
Arotating anode generator equipped with Supper-like total reflection
mirrors and a Mar345 image-plate detector. A mercury derivative
Wcrystal was produced by supplementing a crystallization drop with
A1 mM HgCl2 and soaking a crystal for 10 min. The derivative crystal
fwas soaked in cryoprotectant without the addition of HgCl2 and
flash-frozen for data collection on the rotating anode instrument bbove. Data were collected to 2.6 Å resolution. All data were pro-
essed with the Denzo/HKL package (Otwinowski and Minor, 1997).
tructure Determination and Refinement
he structure was determined by SIRAS (single isomorphous re-
lacement with anomalous scattering) using the HgCl2 derivative
ata and the rotating anode native data. Three mercury atoms were
ocated and refined with respect to their positions, thermal param-
ters, and occupancy using SOLVE (Terwilliger and Berendzen,
999). The SOLVE phases were input to RESOLVE (Terwilliger, 1999;
erwilliger, 2000) for density modification of the resulting map. An
nitial Wee1 model was built automatically into the RESOLVE map
sing MAID (Levitt, 2001). This resulted in a backbone trace for
pproximately 90% of the secondary structure elements. Side
hains were manually built into the experimental electron density
sing O (Jones et al., 1991). Further refinement used the 1.8 Å syn-
hrotron data and iterative cycles of CNS simulated annealing,
onjugate gradient minimization, and B factor refinement (Brünger
t al., 1998). Throughout refinement, 2Fo − Fc maps (including ex-
erimental phases) and the SIRAS map were used for model build-
ng. CNS density-modified maps (solvent flipping) and composite
mit maps further aided the manual building process. All maps
howed clear density for the inhibitor, allowing manual docking and
ositional refinement. Finally, 144 water molecules and 2 Mg2+ ions
identified by octahedral coordination geometry) were located in
o − Fc maps and were refined. The final refinement cycles used
LS and CGMAT refinement in REFMAC (Murshudov et al., 1997)
nd eased restraints.
olecular Modeling
TP was modeled into the Wee1A active site using the programs
YBYL (Blanco, 1991), GOLD (Jones et al., 1995), and MODELLER
Marti-Renom et al., 2000). The glycine-rich loop of the Wee1A
tructure was modified to conform to the more closed conforma-
ion of the cAMPK/ATP/peptide structure (Zheng et al., 1993) using
ODELLER. Side chains in the active site and an additional Mg2+
on were also positioned as in the cAMPK structure. The
D0407824 inhibitor and water molecules were removed, charges
ere assigned to the remaining atoms using SYBYL (Gasteiger
ethod), and an ATP molecule was then docked into the apo struc-
ure using GOLD. GOLD assigned atom types by default, and a
istance restraint between Glu377 O and ATP N6 (min 2.4 Å, max
.2 Å, spring constant 5.0) was included in the GOLD docking pro-
ess to position the adenine moiety of ATP in the back of the
ee1A active-site cleft. GOLD defined the active site by a cavity
earch within 10 Å of Glu377. Multiple GOLD solutions consistently
laced the ATP molecule in the same site, with the ATP phosphates
ound to the active-site magnesium ions. The top solution was
hen subjected to minimization in SYBYL using the Powell method
default parameters).
An octapeptide GEGTYGVV, comprising the target sequence of
DK1, was manually docked into the Wee1A/ATP model. The
entral tyrosine, corresponding to CDK1 Y15, was placed beside
he catalytic Asp426 with its hydroxyl replacing a bound water
olecule and its location also guided by that observed in a peptide
omplex of the insulin receptor tyrosine kinase (Hubbard, 1997).
he remainder of the peptide was placed to complement the
ee1A surface in a conformation similar to that found for peptide
inding to the closely related cAMPK (Zheng et al., 1993). The re-
ulting Wee1A-peptide model was then energy minimized using
NS conjugate gradient minimization with the X-ray term excluded.
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